Rimegepant for cgrp related disorders

Abstract

Disclosed are methods of treating CGRP related disorders, e.g., migraine, by administering to a patient in need thereof rimegepant or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising rimegepant and kits including the pharmaceutical compositions and instructions are also disclosed.

1 - 21 . (canceled) 
     
     
         22 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of rimegepant, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is in a form of an oral solid molded fast-dispersing dosage form. 
     
     
         23 . The pharmaceutical composition of  claim 22 , wherein the rimegepant is in the form of a hemisulfate salt. 
     
     
         24 . The pharmaceutical composition of  claim 22 , wherein the rimegepant is in the form of a hemisulfate sesquihydrate salt. 
     
     
         25 . The pharmaceutical composition of  claim 22 , further comprising gelatin as a carrier. 
     
     
         26 . The pharmaceutical composition of  claim 22 , further comprising mannitol as a filler. 
     
     
         27 . The pharmaceutical composition of  claim 22 , comprising from about 70-80 weight % of the rimegepant or a pharmaceutically acceptable salt thereof, about 10-20 weight % fish gelatin, about 10-20 weight % of a filler, and 0.1-5.0 weight % of a flavorant. 
     
     
         28 . The pharmaceutical composition of  claim 22 , wherein the pharmaceutical composition is capable of disintegrating or dispersing within an interval selected from 1 to 60 seconds, 1 to 30 seconds, 1 to 10 seconds, and 2 to 8 seconds, after being placed in contact with a fluid. 
     
     
         29 . The pharmaceutical composition of  claim 28 , wherein the fluid comprises saliva. 
     
     
         30 . The pharmaceutical composition of  claim 22  in the form of a tablet. 
     
     
         31 . The pharmaceutical composition of  claim 22 , that provides an AUC 0-t  of from about 80-125% of 5000 (hr*ng/mL). 
     
     
         32 . A method of treating migraine in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of rimegepant, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is in a form of an oral solid molded fast-dispersing dosage form. 
     
     
         33 . The method of  claim 32 , wherein the rimegepant is in the form of a hemisulfate salt. 
     
     
         34 . The method of  claim 32 , wherein the rimegepant is in the form of a hemisulfate sesquihydrate salt. 
     
     
         35 . The method of  claim 32 , wherein the pharmaceutical composition further comprises gelatin as a carrier. 
     
     
         36 . The method of  claim 32 , wherein the pharmaceutical composition further comprises mannitol as a filler. 
     
     
         37 . The method of  claim 32 , wherein the pharmaceutical composition comprises from about 70-80 weight % of the rimegepant or a pharmaceutically acceptable salt thereof, about 10-20 weight % fish gelatin, about 10-20 weight % of a filler, and 0.1-5.0 weight % of a flavorant. 
     
     
         38 . The method of  claim 32 , wherein the pharmaceutical composition is capable of disintegrating or dispersing within an interval selected from 1 to 60 seconds, 1 to 30 seconds, 1 to 10 seconds, and 2 to 8 seconds, after being placed in contact with a fluid. 
     
     
         39 . The method of  claim 38 , wherein the fluid comprises saliva. 
     
     
         40 . The method of  claim 32 , wherein the pharmaceutical composition is in the form of a tablet. 
     
     
         41 . The method of  claim 32 , wherein the pharmaceutical composition provides an AUC 0-t  of from about 80-125% of 5000 (hr*ng/mL).